Pan-Cancer Efficacy of Vemurafenib in BRAFV600-Mutant Non-Melanoma Cancers-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Pan-Cancer Efficacy of Vemurafenib in BRAFV600-Mutant Non-Melanoma Cancers

Published:2020-02-06 Issue:5 Volume:10 Page:657-663
ISSN:2159-8274
Container-title:Cancer Discovery
language:en
Short-container-title:Cancer Discov

Author:

Subbiah Vivek^ORCID,Puzanov Igor,Blay Jean-Yves^ORCID,Chau Ian^ORCID,Lockhart A. Craig,Raje Noopur S.,Wolf Juergen,Baselga José,Meric-Bernstam Funda,Roszik Jason^ORCID,Diamond Eli L.^ORCID,Riely Gregory J.,Sherman Eric J.,Riehl Todd,Pitcher Bethany,Hyman David M.

Funder

F. Hoffmann-La Roche Ltd

NIH

NETSARC+ and LYRICAN

Publisher

American Association for Cancer Research (AACR)

Subject

Oncology

Cited by 103 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The ESMO Tumour-Agnostic Classifier and Screener (ETAC-S): a tool for assessing tumour-agnostic potential of molecularly guided therapies and for steering drug development;Annals of Oncology;2024-08

2. Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group;Annals of Oncology;2024-07

3. The evolving landscape of tissue‐agnostic therapies in precision oncology;CA: A Cancer Journal for Clinicians;2024-05-30

4. A critical review of RAF inhibitors in BRAF-mutated glioma treatment;Pharmacogenomics;2024-05-02

5. Genomic deletions explain the generation of alternative BRAF isoforms conferring resistance to MAPK inhibitors in melanoma;Cell Reports;2024-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP